RYR2
Ryanodine receptor 2
As of the edition of 20 October 2026, RYR2 (ryanodine receptor 2, UniProt Q92736) has 2 drugs tested at it and 4 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q92736
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 26
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Cancer; Nervous system; Skin and connective tissue; Hormones; Inherited and neonatal
- Registered trials of its drugs
- 36
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Hydralazine | Marketed | Phase 4 | none listed |
| K201 | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Sterimax | Route B |
| Moberg Pharma | Route A |
| Sequel Pharmaceuticals | Route A |
The other 1 company at RYR2
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at RYR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.